Central Nervous System Post-Transplant Lymphoproliferative Disorder After Kidney Transplantation in an Epstein–Barr Virus–Seronegative Recipient Despite Serial EBV-DNA Monitoring: A Case Report
Transplantation Proceedings · 2026-06 · 58 (5) · 890-895
DOI: 10.1016/j.transproceed.2026.05.001 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplantation Proceedings, 2026-06. Verfasst von Takuya Shimogawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation, Lymphoproliferative Disorders, DNA, Viral, Herpesvirus 4, Human. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation that is strongly associated with Epstein-Barr virus (EBV) infection. Serial monitoring of peripheral blood EBV -DNA is widely used for early detection of PTLD; however, its sensitivity is limited, particularly in cases involving the primary central nervous system. CASE PRESENTATION A 23-year-old female patient underwent living-donor kidney transplantation from her mother and was classified as having standard immunological risk. The EBV serostatus was donor-positive/recipient-negative, and serial peripheral blood EBV-DNA monitoring was performed after transplantation. Despite the EBV-DNA levels remaining below 4 log10 IU/mL, the patient developed progressive neurological symptoms. Subsequent neuroimaging and histopathological evaluations led to the diagnosis of central nervous system PTLD (CNS-PTLD). Treatment consisted of immunosuppression reduction, localized radiotherapy, and systemic rituximab-based chemotherapy and resulted in complete metabolic remission. CONCLUSION Although EBV-DNA levels over 5 log10 IU/mL indicate an urgent concern for PTLD, this case highlights that CNS-PTLD can develop in high-risk transplant recipients even in the absence of significant EBV-DNAemia. Careful clinical assessment and prompt diagnostic evaluation of neurological symptoms are crucial for early diagnosis and appropriate management, particularly in donor-positive/recipient-negative kidney transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
- Department of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan. Electronic address: yamanaga@kumamoto-med.jrc.or.jp.
- Department of Nephrology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
- Department of Urology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Zitieren
APA
Shimogawa, T., Yamanaga, S., Munemura, K., Toyoda, M., Kawabata, C., Miyabe, Y., Yamamoto, Y., Watanabe, Y., Inadome, A., Hidaka, Y., & Yokomizo, H. (2026). Central Nervous System Post-Transplant Lymphoproliferative Disorder After Kidney Transplantation in an Epstein–Barr Virus–Seronegative Recipient Despite Serial EBV-DNA Monitoring: A Case Report. Transplantation Proceedings, 58(5), 890-895. https://doi.org/10.1016/j.transproceed.2026.05.001
Vancouver
Shimogawa T, Yamanaga S, Munemura K, Toyoda M, Kawabata C, Miyabe Y, et al. Central Nervous System Post-Transplant Lymphoproliferative Disorder After Kidney Transplantation in an Epstein–Barr Virus–Seronegative Recipient Despite Serial EBV-DNA Monitoring: A Case Report. Transplantation Proceedings. 2026;58(5):890-895. doi:10.1016/j.transproceed.2026.05.001
BibTeX
@article{Shimogawa2026,
author = {Shimogawa, Takuya and Yamanaga, Shigeyoshi and Munemura, Kazuki and Toyoda, Mariko and Kawabata, Chiaki and Miyabe, Yoei and Yamamoto, Yasuhiro and Watanabe, Yu and Inadome, Akito and Hidaka, Yuji and Yokomizo, Hiroshi},
title = {Central Nervous System Post-Transplant Lymphoproliferative Disorder After Kidney Transplantation in an Epstein–Barr Virus–Seronegative Recipient Despite Serial EBV-DNA Monitoring: A Case Report},
journal = {Transplantation Proceedings},
year = {2026},
volume = {58},
number = {5},
pages = {890--895},
doi = {10.1016/j.transproceed.2026.05.001}
}
EUVIMED